Boston Scientific Corporation (NYSE:BSX) Short Interest Update

Boston Scientific Corporation (NYSE:BSX) saw a large increase in short interest during the month of January. As of January 30th, there was short interest totaling 28,281,105 shares, an increase of 20.8% from the January 15th total of 23,415,429 shares. Approximately 1.9% of the shares of the company are short sold. Based on an average daily volume of 14,359,024 shares, the short-interest ratio is presently 2.0 days. Based on an average daily volume of 14,359,024 shares, the short-interest ratio is presently 2.0 days. Approximately 1.9% of the shares of the company are short sold.

Insider Activity

In other news, EVP Arthur C. Butcher sold 17,313 shares of the company’s stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $101.55, for a total value of $1,758,135.15. Following the sale, the executive vice president owned 23,600 shares in the company, valued at $2,396,580. This represents a 42.32% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Michael F. Mahoney sold 160,901 shares of Boston Scientific stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the completion of the transaction, the chief executive officer directly owned 1,411,735 shares of the company’s stock, valued at $131,983,105.15. The trade was a 10.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 0.50% of the company’s stock.

Hedge Funds Weigh In On Boston Scientific

Several institutional investors have recently modified their holdings of the stock. FWL Investment Management LLC acquired a new stake in shares of Boston Scientific during the second quarter worth about $26,000. Steph & Co. bought a new stake in shares of Boston Scientific in the third quarter valued at about $25,000. Murphy & Mullick Capital Management Corp boosted its position in shares of Boston Scientific by 200.0% during the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock worth $25,000 after buying an additional 170 shares during the period. Financial Consulate Inc. bought a new position in shares of Boston Scientific during the third quarter worth about $25,000. Finally, Swiss RE Ltd. acquired a new stake in Boston Scientific in the 4th quarter valued at approximately $26,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific Stock Performance

Shares of NYSE BSX traded up $1.24 during trading hours on Tuesday, hitting $75.97. 8,158,053 shares of the company’s stock were exchanged, compared to its average volume of 17,228,656. The stock has a market capitalization of $112.62 billion, a price-to-earnings ratio of 39.18, a PEG ratio of 1.03 and a beta of 0.67. The company’s 50-day moving average price is $90.56 and its 200-day moving average price is $97.35. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.51 and a quick ratio of 0.96. Boston Scientific has a 1-year low of $72.69 and a 1-year high of $109.50.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 EPS for the quarter, beating analysts’ consensus estimates of $0.78 by $0.02. The business had revenue of $5.29 billion during the quarter, compared to analyst estimates of $5.29 billion. Boston Scientific had a return on equity of 19.96% and a net margin of 14.44%.Boston Scientific’s revenue was up 15.9% on a year-over-year basis. During the same period in the prior year, the company posted $0.70 earnings per share. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. On average, sell-side analysts expect that Boston Scientific will post 2.85 earnings per share for the current fiscal year.

Analysts Set New Price Targets

BSX has been the subject of several recent analyst reports. Oppenheimer cut their price target on shares of Boston Scientific from $125.00 to $100.00 and set an “outperform” rating for the company in a report on Friday, January 16th. Evercore dropped their price objective on shares of Boston Scientific from $112.00 to $96.00 and set an “outperform” rating for the company in a report on Thursday, February 5th. Canaccord Genuity Group dropped their price target on shares of Boston Scientific from $112.00 to $109.00 and set a “buy” rating on the stock in a research note on Tuesday. Needham & Company LLC cut their price target on Boston Scientific from $121.00 to $97.00 and set a “buy” rating on the stock in a research report on Thursday, February 5th. Finally, Wells Fargo & Company lowered their target price on Boston Scientific from $125.00 to $94.00 and set an “overweight” rating on the stock in a research note on Thursday, February 5th. One investment analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, Boston Scientific has a consensus rating of “Moderate Buy” and an average target price of $109.30.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.